Ascendis Pharma (ASND) Misses Q3 EPS by 48c

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR2.88), EUR0.48 worse than the analyst estimate of (EUR2.40). Revenue for the quarter came in at EUR48.03 million versus the consensus estimate of EUR48.91 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
• Morgan Stanley Resumes Global Payments (GPN) at Equalweight